Similarly, Akil et al. found that serum endocan levels were significantly higher in MS patients than in controls, with notably elevated levels during relapse periods compared with remission, suggesting its potential as a marker for disease activity and relapse dynamics in MS [16]. Here, ESM1 is linked to myeloid sarcoma.